RCC1L: A Potential Drug Target and Biomarker (G81554)

Target Name: RCC1L

NCBI ID: G81554

RCC1L

RCC1L: A Potential Drug Target and Biomarker

RCC1L (Rocher Scientific Company, Inc.) is a drug target (also known as biomarker) that is being investigated for its potential role in the treatment of various diseases, including cancer. RCC1L is a protein that is expressed in various tissues throughout the body , including the brain, lungs, heart, and gastrointestinal tract. It is known to play a role in the development and progression of various diseases, including cancer.

The search for new drug targets is an ongoing process in the pharmaceutical industry. These targets can be identified through various means, including screening through large-scale screening libraries, gene expression profiling, and biochemical assays. Once a potential drug target is identified, further research is conducted to determine its potential as a drug candidate. This process can take many years to complete, and the success of a drug candidate depends on the availability of resources and funding.

RCC1L as a drug target

RCC1L has been identified as a potential drug target due to its unique structure and biology. RCC1L is a transmembrane protein that is expressed in various tissues throughout the body. It consists of a catalytic domain, a transmembrane region, and an optional cytoplasmic tail. The The catalytic domain of RCC1L contains a catalytic active site that is known to play a role in the regulation of cellular processes, including cell signaling and metabolism.

RCC1L has been shown to be involved in various cellular processes that are important for the development and progression of diseases, including cancer. For example, studies have shown that RCC1L is involved in the regulation of cell proliferation, apoptosis (programmed cell death), and angiogenesis (the formation of new blood vessels). It is also involved in the regulation of cellular signaling pathways, including the TGF-β pathway, which is involved in the development and progression of cancer.

In addition to its involvement in cellular processes, RCC1L has also been shown to play a role in the regulation of various signaling pathways that are important for the development and progression of diseases. For example, studies have shown that RCC1L is involved in the regulation of the PI3K/Akt signaling pathway, which is involved in the development and progression of cancer. This pathway is known to be involved in the regulation of various cellular processes, including cell signaling, angiogenesis, and metabolism.

RCC1L as a biomarker

RCC1L has also been shown to be potential biomarker for various diseases, including cancer. Studies have shown that RCC1L is expressed in various tissues throughout the body, including the brain, lungs, heart, and gastrointestinal tract. This suggests that RCC1L may be a useful biomarker for the diagnosis and treatment of diseases that affect these tissues.

In addition to its potential as a drug target, RCC1L has also been shown to be a potential biomarker for cancer. Studies have shown that RCC1L is expressed in various tissues throughout the body, including the brain, lungs, heart, and gastrointestinal tract. This suggests that RCC1L may be a useful biomarker for the diagnosis and treatment of cancer.

Conclusion

RCC1L is a protein that has been identified as a potential drug target and biomarker for the treatment of various diseases, including cancer. Its unique structure and biology make it an attractive candidate for further research. Further studies are needed to determine its potential as a drug and to explore its potential as a biomarker for the diagnosis and treatment of various diseases.

Protein Name: RCC1 Like

Functions: Guanine nucleotide exchange factor (GEF) for mitochondrial dynamin-related GTPase OPA1. Activates OPA1, by exchanging bound GDP for free GTP, and drives OPA1 and MFN1-dependent mitochondrial fusion (PubMed:28746876). Plays an essential role in mitochondrial ribosome biogenesis. As a component of a functional protein-RNA module, consisting of RCC1L, NGRN, RPUSD3, RPUSD4, TRUB2, FASTKD2 and 16S mitochondrial ribosomal RNA (16S mt-rRNA), controls 16S mt-rRNA abundance and is required for intra-mitochondrial translation of core subunits of the oxidative phosphorylation system (PubMed:27667664)

The "RCC1L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RCC1L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets